TELO
TSXV:TELOTSXV
8 announcements
Credibility Score60%
Telo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells
OverhypedModerate hypeunclear
Telo Genomics signs a term sheet for a potential global AI cancer detection license.
18 Nov 2026, 11:30 UTC
▼
Telo Genomics Announces $250,000 Term Loan Facility
Routineunclear
Telo Genomics secures $250,000 loan, receives $100,000 initial advance at 15.60% annual interest.
6 Nov 2026, 21:00 UTC
▼
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
OverhypedModerate hypeunclear
Telo Genomics advances multi-center MRD assay validation, targeting commercialization by end-2027.
29 Oct 2026, 10:30 UTC
▼
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Overhypedunclear
TSXV:TELO reports preclinical tumor suppression, but offers no numbers or clinical roadmap.
10 Aug 2026, 15:28 UTC
▼
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
OverhypedModerate hypeunclear
Technical progress is real, but commercial value is years away and unproven.
16 Jul 2026, 11:02 UTC
▼
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
OverhypedModerate hypeunclear
Patent filing signals R&D progress, but commercial impact is distant and unproven.
9 Jul 2026, 11:12 UTC
▼
Telo Genomics Announces Termination of Investor Relations Agreement
RoutineModerate hypeunclear
No financials, just biotech promises and a terminated IR contract—wait for real results.
27 Jun 2026, 01:03 UTC
▼